API | Indication | Micronised / PSD | CEP | EU DMF | US DMF | JP DMF | KR DMF | CN DMF | RU DMF |
---|---|---|---|---|---|---|---|---|---|
Aclidinium bromide | COPD | • | • | • | |||||
Arformoterol tartrate (A) | COPD | • | • | • | • | ||||
Arformoterol tartrate (D) p | COPD | • | • | • | • | ||||
Formoterol fumarate | Asthma and COPD | • | • | • | • | • | • | • | |
Glycopyrrolate bromide p | COPD | • | • | • | • | • | • | ||
Indacaterol acetate | Asthma | ||||||||
Indacaterol maleate p | Asthma and COPD | • | • | • | • | • | • | ||
Montelukast sodium p | Asthma, allergic & seasonal rhinitis | • | • | ||||||
Olodaterol p | COPD | • | • | • | |||||
Revefenacin | COPD | • | • | • | |||||
Salmeterol xinafoate p | Asthma and COPD | • | • | • | • | • | |||
Tiotropium bromide | COPD | • | • | • | • | ||||
Umeclidinium bromide | COPD | • | • | • | • | ||||
Vilanterol trifenatate | Asthma and COPD | • | • | • |
P = Patent applications/granted patents owned by Neuraxpharm
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© INKE. All rights reserved.